Coherus Biosciences Inc (NASDAQ:CHRS) has a beta value of 0.54 and has seen 3.53 million shares traded in the last trading session. The company, currently valued at $247.22M, closed the last trade at $2.22 per share which meant it gained $0.05 on the day or 2.30% during that session. The CHRS stock price is -289.64% off its 52-week high price of $8.65 and 35.59% above the 52-week low of $1.43. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.2 million shares traded. The 3-month trading volume is 6.14 million shares.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Sporting 2.30% in the green in last session, the stock has traded in the red over the last five days, when the CHRS stock price touched $2.22 or saw a rise of 12.94%. Year-to-date, Coherus Biosciences Inc shares have moved -33.33%, while the 5-day performance has seen it change -7.11%. Over the past 30 days, the shares of Coherus Biosciences Inc (NASDAQ:CHRS) have changed -18.38%. Short interest in the company has seen 24.2 million shares shorted with days to cover at 7.47.
Coherus Biosciences Inc (CHRS) estimates and forecasts
Figures show that Coherus Biosciences Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -53.56% over the past 6 months, with this year growth rate of 83.33%, compared to 13.60% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 74.70% and 60.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be 34.20%.
6 analysts offering their estimates for the company have set an average revenue estimate of $91.52 million for the current quarter. 6 have an estimated revenue figure of $69.02 million for the next quarter concluding in Jun 2024.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 4.73% over the past 5 years.
CHRS Dividends
Coherus Biosciences Inc is expected to release its next earnings report on March 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
Insiders own 1.37% of the company shares, while shares held by institutions stand at 78.99% with a share float percentage of 80.09%. Investors are also buoyed by the number of investors in a company, with Coherus Biosciences Inc having a total of 221 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 15.79 million shares worth more than $67.41 million. As of Jun 29, 2023, Blackrock Inc. held 16.71% of shares outstanding.
The other major institutional holder is Vanguard Group Inc, with the holding of over 8.85 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $37.79 million and represent 9.37% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and JP Morgan Small Cap Growth Fund. As of Jun 29, 2023, the former fund manager holds about 2.89% shares in the company for having 2.73 million shares of worth $11.66 million while later fund manager owns 2.44 million shares of worth $10.41 million as of Jun 29, 2023, which makes it owner of about 2.58% of company’s outstanding stock.
